Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced topline results from the Phase 3 CYPRESS study evaluating the efficacy and safety of ampreloxetine ...

Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced that the Food and Drug Administration (FDA) ...

If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. LUND, Sweden, March 4, 2026 /PRNewswire/ -- Hansa Biopharma ...

Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, has been selected as a late breaking abstract to present Phase II interim data ...

ZURICH, March 4, 2026 /PRNewswire/ -- Fapon Biopharma today announced that Dr. Kaiqing Zhang, Ph.D., Associate Director of Business/Corporate Development, will deliver a company presentation at the ...

Phase 3 CYPRESS study did not meet the primary endpoint, the OHSA Composite Score, a patient reported outcome (PRO) Cash of $326.5 million at Q4 2025 (no debt); ...

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), ...

(Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company’s management team will ...

Antibody therapies work in part by binding to Fc receptors, proteins found on immune cells that control key immune functions such as antibody-mediated cell killing and inflammation. Since these ...

Antibody therapies are changing the treatment of cancer, inflammatory diseases and infections. However, many promising drug ...

Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseases.

CLEVELAND, March 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth ...